摘要
目的观察大剂量阿托伐他汀治疗介入术后冠心病患者的疗效。方法选取介入治疗术后冠心病(CHD)患者76例,随机分为观察组和对照组,每组38例。对照组在常规治疗基础上给予常规剂量(20mg/d)阿托伐他汀,观察组在常规治疗基础上给予大剂量阿托伐他汀(80 mg/d),疗程均为2个月。观察两组治疗期间心脏缺血事件(心绞痛、血运重建、再次入院)发生情况;检测治疗前、后血脂及C反应蛋白(hs-CRP)水平;记录不良反应情况。结果对照组和观察组发生心脏缺血事件的概率分别为21.1%和7.9%(P<0.05)。治疗后两组胆固醇(TC)、低密度脂蛋白(LDL-C)和C反应蛋白(hs-CRP)均较治疗前改善(P均<0.05),但观察组改善效果均优于对照组(P均<0.05)。治疗后观察组2例、对照组1例出现丙氨酸氨基转移酶升高(P>0.05)。结论大剂量阿托伐他汀治疗介入术后CHD患者安全、有效。
Objective To observe the clinical effects of large dose atorvastatin on coronary heart disease(CHD) after percutaneous coronary intervention. Methods 76 patients with CHD after percutaneous coronary intervention were randomly divided into observation group and control group with 38 cases in each. Control group was given conventional treatment, in addition to regular dose of atorvastatin(20 mg/d); observation group was given the same conventional treatment, in addition to large dose of atorvastatin(80 mg/d); course of treatment was 2 months. To compare cardiac ischemia probability of two groups; to measure blood lipid and hs- CRP before and after treatment; to record adverse reaction in two groups. Results The cardiac ischemia probability rate of observation group and control group were 21.1% and 7.9% respectively(P<0.05). The levels of TC, LDL-C and hs-CRP in observation group were better than those in control group(all P<0.05). Adverse reactions of two groups were no significant difference(P>0.05). Conclusions High dose atorvastatin in patients with CHD after percutaneous coronary intervention is one of the relatively safe, effective treatment.
出处
《慢性病学杂志》
2014年第3期171-173,共3页
Chronic Pathematology Journal
